Former HUD Secretary Dr. Ben Carson, Sr. will assist Galectin Therapeutics Inc. (NSDQ: GALT) with the development of its galectin-3 inhibitor, belapectin. The drug is a potential treatment for nonalcoholic steatohepatitis (NASH), which is also known as nonalcoholic fatty liver disease.  Galectin Therapeutics has an ongoing Phase 2b/3 trial to investigate belapectin’s potential in treating cirrhosis…